<DOC>
	<DOCNO>NCT00690456</DOCNO>
	<brief_summary>The primary objective study determine effect rimonabant 20 mg daily add ongoing metformin therapy glycemic control ( HbA1c ) 36 week period patient type 2 diabetes . Secondary objective include evaluation marker glycemic control , lipid profile , body weight , abdominal obesity . Also , trial study safety rimonabant add metformin period 47 week .</brief_summary>
	<brief_title>Effect Rimonabant Metformin Combination Glycemic Control Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The total duration per patient approximately 49 week include 36-week double-blind treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>History type 2 diabetes HbA1c 7 % 10 % screen visit Treatment metformin fix stable dose 1500 mg/day least past 3 month prior screen visit Within 3 month prior screen visit : change lipid modify agent , administration systemic corticosteroid 10 day , use antiobesity agent drug weight loss Weight loss 5 kg within 3 month prior screen Administration investigational drug within 30 day prior screen visit Prior exposure type 1 cannabinoid receptor ( CB1 ) antagonists include rimonabant Presence history cancer within past five year Pregnant breastfeed woman Presence severe medical psychological condition , opinion investigator , would compromise patient 's safe participation include uncontrolled serious psychiatric illness major depression within last 2 year , history severe psychiatric disorder . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Metformin</keyword>
</DOC>